Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ASCL1 regulates and cooperates with FOXA2 to drive terminal neuroendocrine phenotype in prostate cancer.

JCI insight - 6 Dec 2024

Nouruzi Shaghayegh, Namekawa Takeshi, Tabrizian Nakisa, Kobelev Maxim, Sivak Olena, Scurll Joshua M, Cui Cassandra Jingjing, Ganguli Dwaipayan, Zoubeidi Amina

Abstract excerpt

Lineage plasticity mediates resistance to androgen receptor pathway inhibitors (ARPIs) and progression from adenocarcinoma to neuroendocrine prostate cancer (NEPC), a highly aggressive and poorly understood subtype. Neuronal transcription factor ASCL1 has emerged as a central regulator of the lineage plasticity driving neuroendocrine differentiation. Here, we showed that ASCL1 was reprogrammed in ARPI-induced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Basic Helix-Loop-Helix Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Neuroendocrine

Share to Hepatocyte Nuclear Factor 3-beta

Share to Homeodomain Proteins

Share to Neuroendocrine Tumors

Share to Prostatic Neoplasms

Share to Receptors, Androgen

Source

Open in PubMed Open full text

Identifiers

PMID: 39470735
DOI: 10.1172/jci.insight.185952
PMCID: PMC11623946

Genes

ASCL1
FOXA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ASCL1 regulates and cooperates with FOXA2 to drive terminal neuroendocrine phenotype in prostate cancer.PMID 39470735Read ↗

Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1Semantic proximity Read ↗

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.Semantic proximity Read ↗

Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancerSemantic proximity Read ↗

A MYC Family Switch: L-MYC Drives and Maintains Neuroendocrine Lineage Programs in Prostate CancerSemantic proximity Read ↗

Longitudinal single-cell profiling links RUNX1T1 to lineage transition and maintenance in treatment-induced neuroendocrine prostate cancerSemantic proximity Read ↗

Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancerSemantic proximity Read ↗

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancerSemantic proximity Read ↗

Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiationSemantic proximity Read ↗

Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancerSemantic proximity Read ↗

Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer ProgressionSemantic proximity Read ↗

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate CancerSemantic proximity Read ↗

N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.